A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom

Value in Health

Volumn 11, Issue 3, 2008, Pages 376-388

  Cottrell, Suzi ^a   Tilden, Dominic ^a   Robinson, Paul ^a   Bae, Jay ^b   Arellano, Jorge ^b   Edgell, Eric ^b   Aristides, Mike ^a   Boye, Kristina S ^b  

^a IQVIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

ADHD; Atomoxetine; Cost utility analysis; Economic evaluation; Markov process; Methylphenidate; Monte Carlo simulation

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE; PLACEBO;

ALGORITHM; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; COMORBIDITY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIZZINESS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG SAFETY; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MONTE CARLO METHOD; NERVOUSNESS; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIDE EFFECT; SOMNOLENCE; STOMACH PAIN; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 44049084834     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00256.x     Document Type: Article

References (47)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th revised edn 2000 American Psychiatric Press Washington, DC
2. J Biederman Attention-deficit/hyperactivity disorder: a life-span perspective J Clin Psychiatry 59 Suppl. 7 1998 S4 16
3. J Biederman E Mick SV Farone Age-dependent decline of symptoms of attention-deficit hyperactivity disorder: impact of remission definition and symptom type Am J Psychiatry 157 2000 816 818
4. RA Barkley M Fischer CS Edelbrock The adolescent outcome of hyperactive children diagnosed by research criteria. I. An 8-year prospective follow-up study J Am Acad Child Adolesc Psychiatry 29 1990 546 557
5. RA Barkley DC Guevremont AD Anastopoulos Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey Pediatrics 92 1993 212 218
6. S Mannuzza RG Klein A Bessler Adult psychiatric status of hyperactive boys grown up Am J Psychiatry 155 1998 493 498
7. S Mannuzza RG Klein N Bonagura Hyperactive boys almost grown up. V. Replication of psychiatric status Arch Gen Psychiatry 48 1991 77 83
8. EL Hart BB Lahey R Loeber Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study J Abnorm Child Psychol 23 1995 729 749
9. P Rasmussen C Gillberg Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study J Am Acad Child Adolesc Psychiatry 39 2000 1424 1431
10. National Institute for Health and Clinical Excellence (NICE) TA98 Methylphenidate, atomoxetine and dexamfetamine for attention defecit hyperactivity disorder (ADHD) in children and adolescents—guidance Available from: http://guidance.nice.org.uk/TA98/guidance/pdf/English/download.dspx [Accessed July 31, 2007].
11. JR Parr A Ward S Inman Current practice in the management of attention deficit disorder with hyperactivity (ADHD) Child Care Health Dev 29 2003 215 218
12. S King S Griffin Z Hodeges Assessment Report: Attention Deficit Hyperactivity Disorder—Methylphenidate, Atomoxetine and Dexamfetamine (Review) [Online]. Report commissioned by the NHS R&D HTA Programme Available from: http://www.nice.org.uk/pdf/ADHD_assessment_report.pdf [Accessed May 16, 2005].
13. National Institute For Clinical Excellence (NICE) Appraisal Consultation Document—Methylphenidate, Atomoxetine and Dexamfetamine for Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents [Online] Available from: http://www.nice.org.uk/page.aspx?o=247360 [Accessed May 16, 2005].
14. Sutton V, Sumner C, Allen AJ, et al. Validity, reliability, and responsiveness of the DPREM-R scale for ADHD [abstract]. American Academy of Child and Adolescent Psychiatry 50th Annual Meeting, October 14–19, 2003; Miami, Florida.
15. DK Kelsey CR Sumner CD Casat Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial Paediatrics 114 2004 1 8
16. WE Pelham EM Gnagy L Burrows-Maclean Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings Pediatrics 107 2001 6 15
17. J Swanson S Gupta A Lam Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof of concept and proof of product studies Arch Gen Psychiatry 60 2003 204 211
18. ML Wolraich LL Greenhill W Pelham Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder Pediatrics 108 2001 883 892
19. TE Brown Emerging understanding of attention-deficit disorders and comorbidities TE Brown Attention-Deficit Disorders and Comorbidities in Children, Adolescents, and Adults 2000 American Psychiatric Press, Inc. Washington, DC
20. Electronic Medicines Compendium (eMC) [Online] Available from: http://www.medicines.org.uk/emc.aspx [Accessed January 20, 2004].
21. Newcorn JH, Zhang S, Rogers AK, et al. Atomoxetine treatment response in ADHD patients naïve to previous pharmacotherapy [abstract]. American Academy of Child and Adolescent Psychiatry 51th Annual Meeting; October 19–24, 2004, Washington, DC.
22. D Efron F Jarman M Barker Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial Pediatrics 100 1997 E6
23. DATA Prof (tm) 2003 TreeAge Software Williamstown, MA
24. I Banino Attention Deficit Hyperactivity Disorder; MP3 EC 056 2003 Eli Lilly Indianapolis, IN (Data on file).
25. MIMS Monthly Index of Medical Specialities. June 2004 2004 Haymarket Medical Publications Limited London
26. K Secnik L Matza S Cottrell Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom Med Decis Making 25 2005 56 70
27. T Spencer JH Heiligenstein J Biederman Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder J Clin Psychiatry 63 2002 1140 1147
28. K Conners Clinical Study Report: A Randomized, Double-Blind Study of Tomoxetine Hydrochloride, Methylphenidate Hydrochloride, and Placebo in Pediatric Outpatients with Attention-Deficit/Hyperactivity Disorder 2000 Eli Lilly Indianapolis, IN (Data on file).
29. D Michelson AJ Allen J Busner Once-daily atomoxetine treatment for children and adolescents with attention deficit disorder: a randomized, placebo-controlled study Am J Psychiatry 159 2002 1 6
30. D Michelson D Faries J Wernicke Atomoxetine in the treatment of children and adolescents with attention deficit/hyperactivity disorder: a randomised, placebo-controlled, dose–response study Pediatrics 108 2001 e83
31. D Michelson AJ Allen J Busner Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study Am J Psychiatry 159 2002 1896 1901
32. M Weiss R Tannock C Kratochvil A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD J Am Acad Child Adolesc Psychiatry 44 2005 647 655
33. H Quintana DK Kelsey Draft Clinical Study Report: Randomized, Double-Blind, Placebo-Controlled Trial of Once Daily Atomoxetine Hydrochloride to Evaluate Efficacy in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children Ages 6–12 with an Assessment of Evening Behavior 2002 Eli Lilly Indianapolis, IN (Data on file).
34. R Kurlan AJ Allen D Gilbert Atomoxetine treatment in children with ADHD and comorbid tic disorders Neurology 65 2005 1941 1949
35. Gillberg C, Lothgren M, Fitzgerald P, et al. Atomoxetine versus methylphenidate as a treatment for ADHD in children and adolescents: a meta-analysis of safety data incorporating active comparator and placebo controlled trials [abstract/poster presentation]. European Society for Child and Adolescent Psychiatry (ESCAP); September 28–October 1, 2003, Paris, France.
36. HM Schachter B Pham J King How efficacious and safe is short-term acting methylphenidate for the treatment of attention deficit disorder in children and adolescents? A meta-analysis CMAJ 165 2001 1475 1488
37. Temporal Course of Treatment-Emergent Adverse Events during Atomoxetine Treatment in the Overall ADHD Analysis Group 2003 Eli Lilly Indianapolis, IN (Data on file).
38. Results of a Questionnaire Concerning Attention Deficit Hyperactivity Disorder and Standard Practice in the Secondary Care Setting in the UK. A Study Conducted by M-TAG for Eli Lilly 2003 Eli Lilly Indianapolis, IN (Data on file).
39. Bae JP. Meta-regression Analysis of Efficacy in Atomoxetine Randomized Controlled ADHD Trials. [Podium Presentation]. European International Society of Pharmacoeconomic and Outcomes Research (E-ISPOR); November 6–November 9, 2004, Florence, Italy.
40. CJ Kratochvil JH Heiligenstein R Dittman Atomoxetine and methylphenidate treatment in children with ADHD: a prospective andomized, open-label trial J Am Acad Child Adolesc Psychiatry 41 2002 776 784
41. J Biederman D Michelson Clinical Study Report: Randomized, Double-Blind, Placebo-Controlled, Variable Discontinuation Study of Tomoxetine Hydrochloride in Children with Attention-Deficit/Hyperactivity Disorder 2001 Eli Lilly Indianapolis, IN (Data on file).
42. P Trzepacz Abbreviated Clinical Study Report. Sleep and Cognitive/Neuropsychological Function in Children with Attention-Deficit/Hyperactivity Disorder before and during Treatment with Tomoxetine Hydrochloride and Stimulants 2003 Eli Lilly Indianapolis, IN (Data on file).
43. Michelson D. B4Z-MC-LYBI: a double-blind, placebo-controlled comparison of atomoxetine, Oros® methylphenidate, and placebo [abstract for symposium presentation]. American Academy of Child and Adolescent Psychiatry 51th Annual Meeting; October 19–24, 2004, Washington, DC.
44. D Michelson JK Buitelaar M Danckaerts Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study J Am Acad Child Adolesc Psychiatry 43 2004 896 904
45. JK Buitelaar D Michelson Clinical Study Report: Relapse Prevention after 10-Week and 52-Week Treatment with Tomoxetine Hydrochloride in Children with Attention-Deficit/Hyperactivity Disorder 2003 Eli Lilly Indianapolis, IN (Data on file).
46. LE Arnold Methylphenidate versus amphetamine: comparative review J Atten Disord 3 2000 200 211
47. D Efron F Jarman M Barker Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial Pediatrics 100 1997 662 666